All In Biotech

Drug Trial Radar · NCT00720798

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies

Last checked: Nov 20, 2026Latest source record: Sep 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,067

Actual

Start

Sep 2005

Primary completion

Apr 2013

Study completion Apr 2013

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.

Conditions

  • Rheumatoid Arthritis

Interventions

  • TocilizumabDrug

    For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.

  • Disease-modifying anti-rheumatic drugsDrug

    Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.

  • Non-steroidal anti-inflammatory drugsDrug

    Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.

  • Oral corticosteroidsDrug

    Oral corticosteroids (≤ 10 mg/day) were permitted during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With ≥ 1 Adverse EventTime frame: Baseline to the end of the study (up to 7 years, 7 months)

Locations

295 sites in 34 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Paradise Valley, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Long Beach, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palm Desert, California

  • Site not named

    Palm Springs, California

  • Site not named

    Palo Alto, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Jose, California

  • Site not named

    San Leandro, California

  • Site not named

    Santa Maria, California

  • Site not named

    Torrance, California

  • Site not named

    Upland, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Newark, Delaware

  • Site not named

    Aventura, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Palm Habor, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Meridian, Idaho

Showing 40 of 295 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.